Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
per week
for 24 weeks
// //

Biolase Inc NASDAQ: BIOL-Q

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Recent Studies Demonstrate BIOLASE's Waterlase Laser Technology is Beneficial for Treatment of Peri-Implantitis

PR Newswire - PRF - Thu Jun 3, 8:00AM CDT

FOOTHILL RANCH, Calif. , June 3, 2021 /PRNewswire/ --  BIOLASE, Inc.  (NASDAQ: BIOL), the global leader in dental lasers, announced today that recent data published in two journals, the I nternational Journal of Periodontics & Restorative Dentistry and Lase rs in Medical Science , demonstrates BIOLASE's Waterlase Er,Cr:YSGG laser technology can be beneficial for the treatment of peri-implantitis in patients suffering from the inflammatory disease.

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

In a first-of-its-kind human histological study led by Dr. Myron Nevins , researchers reported that the Er,Cr:YSGG laser has a positive role in debridement of a titanium implant surface to facilitate subsequent regenerative treatment. The findings suggest the value that BIOLASE's Waterlase technology has for dentists who are seeking devices that can assist in periodontal treatments.

Similarly, data published in Lasers in Medical Science by Drs. David M. Kim and Dr. Chia-Yu (Jennifer) Chen , displays that the Er,Cr:YSGG laser effectively decreases bacteria from zirconia discs. Furthermore, fibroblast attachments on the surfaces of the zirconia discs show more adherence when treated with Er,Cr:YSGG laser technology. There is a significant increase in the number of zirconia dental implants being placed throughout the world.

"Although studies can vary, data suggests as much as 56% of people with dental implants may have peri-implantitis," said John Beaver , CEO of BIOLASE. "Unfortunately, treatment methods for peri-implantitis can be painful, costly, ineffective and unpredictable. The findings of these recent studies confirm that Waterlase laser technology can be a more viable treatment option than alternative methods. We look forward to continuing to provide dentists with minimally invasive treatment options through advanced laser technology that benefits their patients."

To learn more about BIOLASE's Waterlase laser and other available laser technologies, visit .

About BIOLASE, Inc.

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus ® , Waterlase Express™, and laser dentistry, find BIOLASE online at , Facebook at , Twitter at , Instagram at , and LinkedIn at .

BIOLASE ® , Waterlase ® and Waterlase iPlus ® are registered trademarks of BIOLASE, Inc.

Cision View original content to download multimedia:


comtex tracking


More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies